ArticleBiomedical reports2026
Prognostic and therapeutic importance of TROP-2 and MUC-1 in non-small cell lung cancer: A systematic review and meta-analysis.
Article in Biomedical reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) represents ~85% of all lung cancer and is a leading cause of cancer-related mortality worldwide. Trophoblast cell surface antigen-2 (TROP-2) and mucin-1 (MUC-1) have emerged as potential prognostic biomarkers and therapeutic targets. There are no reports of their combined impact as a biomarker in NSCLC. The present systematic review/meta-analysis aimed to evaluate the expression patterns and prognostic implications of TROP-2 and MUC-1 in NSCLC. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and the Population, Intervention, Comparison, and Outcome framework, 1,297 publications between 2019 and 2024 were systematically retrieved from PubMed, Scopus and EMBASE databases. A total of 12 studies (three for TROP-2 and nine for MUC-1) met the inclusion criteria and five (two for TROP-2 and three for MUC-1) were finally included in the final meta-analysis using fixed-effect models involving 1,159 patients. High TROP-2 [hazard ratio (HR) 1.43, 95% confidence interval (CI): 1.15-1.79; P=0.002] and MUC-1 (HR 2.25; 95% CI: 1.57-3.23, P<0.0001) were consistently overexpressed in NSCLC patient tissues. An exploratory pooled analysis of both biomarker groups demonstrated a significant association with poor clinical outcomes and short survival (HR 1.62; 95% CI: 1.34-1.96; P<0.00001), though this should not be interpreted as evidence of a true dual-biomarker effect. Mechanistically, both markers promote cancer cell proliferation, epithelial-mesenchymal transition, immune evasion and treatment resistance. In conclusion, TROP-2 and MUC-1 are valuable prognostic biomarkers in NSCLC. Their overexpression correlates with poor survival, supporting the development of targeted therapies in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.